Journal: International journal of oncology

Article Title: Immune adjuvant effect of Juzentaihoto, a Japanese traditional herbal medicine, on tumor vaccine therapy in a mouse model.

doi: 10.3892/ijo.2015.3208

Figure Lengend Snippet: Figure 5. JTT enhances cellular and humoral immune responses to the OVA vaccine in vivo. One group was administered JTT (2 g/kg/day) and the other was administered water once a day. OVA + Water group: water was orally administered to 3 mice from day 7 to day 14 consecutively. In addition, these mice were immunized with OVA on day 7 and day 0 twice. OVA + JTT group: JTT was orally administered to 3 mice from day 7 to day 14 consecutively. In addition, these mice were immunized with OVA on day 7 and day 0 twice. On day 14, mice of this group were sacrificed, and the splenocytes and serum were collected. Splenocytes were re-stimulated with OVA (10 µg/ml). (A) OVA-specific IgG2a in mouse serum immunized with OVA with or without the administration of JTT or water was determined by ELISA. The relative ratio of OVA-specific IgG2a is shown comparing the OVA + JTT group with the OVA + Water group. Each group contained 3 mice and all experiments were repeated 3 times. Data are the mean ± SD; *P<0.05, compared with the control (OVA + Water) group. (B) Data are expressed as spot-forming IFN-γ-secreting T cells (SFC) responding to OVA by ELISPOT assay (SFC/1x105 splenocytes). Each group contained 3 mice and all experiments were repeated 3 times. Data are the mean ± SD; *P<0.05, **P<0.01, compared with the control (OVA + Water) group.

Article Snippet: Unbound OVA on the plate was removed by washing, and the plate was further incubated with blocking reagent (Morinaga Institute of Biological Science, Inc., Yokohama, Japan) at 37 ̊C for 1 h. Dilutions of mouse serum immunized with OVA with or without the administration of JTT were added to the wells (100 μl/well) and incubated at 37 ̊C for 1 h. After washing, anti-mouse IgG1-HRP (15H6, G1 chain specific; SouthernBiotech, AL, USA) or IgG2a-HRP (HOPC-1, G2a chain specific; SouthernBiotech) was added to the wells and incubated at 37 ̊C for 1 h. These IgG1 and IgG2 levels were determined using TMBz (3,3',5,5'-tetramethylbenzidine; Dojindo, Kumamoto, Japan) according to the manufacturer's instructions.

Techniques: In Vivo, Enzyme-linked Immunosorbent Assay, Control, Enzyme-linked Immunospot

Journal: bioRxiv

Article Title: Membrane localisation and checkpoint blockade enhance xenoantigen delivery to redirect pre-existing immunity against tumours

doi: 10.64898/2026.03.01.708859

Figure Lengend Snippet: A) Experimental timeline of the immunisation (i.e., vaccination) against OVA and subsequent tumour inoculation of the OVA-expressing B16F10 cell lines in mice. B) Titers of anti-OVA IgG per IgG subtypes in the plasma of the mice at d18. C) Percentage of OVA-specific CD8 + T cells against the immunogenic epitope OVA 257-264 (SIINFEKL) in the blood at d18 in pre-immunised mice (vax) or naïve mice (no vax) (n ≥ 3, mean ± SD, unpaired t-test). D, E) B16F10 melanoma cells, either wild-type (WT) or genetically modified to express high ( HI ) or low ( LO ) doses of membrane-bound OVA (B16mOVA) or soluble OVA (B16-OVA), were injected intradermally in C57BL/6 mice. Tumour growth (D) and associated survival (E) of the different OVA-expressing B16 cell lines in pre-immunised mice (n ≥ 5, mean ± SEM, Kruskal-Wallis with Dunn’s post-test on d10, d14 or d26 for tumour growth, log-rank tests for survival). F) Potential anti-tumour mechanisms engaged by soluble (left) or membrane-bound (right) xenoantigens when expressed by cancer cells.

Article Snippet: Samples were applied to the antigen coated plate and incubated at RT for 2 h. The plates were washed three times with PBST and HRP-conjugated antibodies were used to detect antigen-specific antibodies: anti-mouse IgG1 (#1070-05), anti-mouse IgG2a (#1080-05), anti-mouse IgG2b (#1090-05) and anti-mouse IgG3 (#1100-05) from Southern Biotech (Birmingham, AL, USA).

Techniques: Expressing, Clinical Proteomics, Genetically Modified, Membrane, Injection

Journal: bioRxiv

Article Title: Membrane localisation and checkpoint blockade enhance xenoantigen delivery to redirect pre-existing immunity against tumours

doi: 10.64898/2026.03.01.708859

Figure Lengend Snippet: A) Immunofluorescent staining of B16F10 WT melanoma with the TRP1-targeting TA99 antibody (scale bar = 100 μm). B) B16F10 WT tumour growth upon treatment with TA99 or IgG2a isotype control (n ≥ 4, mean ± SEM, Mann-Whitney test on d11). C) Design of FabTRP-OVA fusion protein and analysis of its production by SDS-PAGE (expected size = 92,3 kDa). D) Illustration of the FabTRP-OVA fusion protein approach for targeting the xenoantigen to the cancer cell membrane. E) Representative flow cytometry plot of FabTRP-OVA, OVA and no OVA (i.e., secondary antibody only) binding to the surface of B16F10 WT cells. F) B16F10 WT tumour growth when treated with FabTRP-OVA in pre-immunised or naïve mice (n ≥ 4, mean ± SEM, Kruskal-Wallis with Dunn’s post-test on d12). G) B16F10 WT tumour growth when treated with FabTRP-OVA in combination with anti-PD-1 checkpoint blocade therapy (n ≥ 4, mean ± SEM, Kruskal-Wallis with Dunn’s post-test on d12). H) Experimental treatment timeline of xenoantigen delivery (i.e., FabTRP-OVA, OVA or PBS (vehicle only)) and anti-PD-1 checkpoint blockade therapy in B16F10 WT in mice pre-immunised against OVA (Vax) or naïve (No vax). I, J) B16F10 WT tumour growth (I) and associated mouse survival (J) upon treatment with FabTRP-OVA, OVA or PBS in combination with anti-PD-1 checkpoint blockade therapy (n ≥ 5, mean ± SEM, Kruskal-Wallis with Dunn’s post-test on d16, log-rank tests for survival).

Article Snippet: Samples were applied to the antigen coated plate and incubated at RT for 2 h. The plates were washed three times with PBST and HRP-conjugated antibodies were used to detect antigen-specific antibodies: anti-mouse IgG1 (#1070-05), anti-mouse IgG2a (#1080-05), anti-mouse IgG2b (#1090-05) and anti-mouse IgG3 (#1100-05) from Southern Biotech (Birmingham, AL, USA).

Techniques: Staining, Control, MANN-WHITNEY, SDS Page, Membrane, Flow Cytometry, Binding Assay

Journal: bioRxiv

Article Title: Membrane localisation and checkpoint blockade enhance xenoantigen delivery to redirect pre-existing immunity against tumours

doi: 10.64898/2026.03.01.708859

Figure Lengend Snippet: A) Experimental timeline of the immunisation (i.e., vaccination) against varicella VZVO using Varivax or a combination of gE/CpG. B) IFΝγ quantification in the supernatant of gE restimulated (+) or non-restimulated (-) splenocytes, collected from mice immunized with Varivax, gE/CpG or PBS (i.e., naïve). Ionomycin+PMA was used as a positive control. C) Titers of anti-gE total IgG and per IgG subtypes in the plasma of the pre-immunised mice at d55 (before tumour implantation). D) Experimental treatment timeline of xenoantigen delivery (i.e., Varivax, gE or PBS (vehicle only)) and anti-PD-1 checkpoint blockade treatment in B16F10 WT in mice pre-immunised with Varivax against varicella VZVO . E, F) B16F10 WT tumour growth (E) and associated mouse survival (F) upon treatment with Varivax, gE or PBS in combination with anti-PD-1 checkpoint blockade (n ≥ 7, mean ± SEM, Kruskal-Wallis with Dunn’s post-test on d16, log-rank tests for survival).

Article Snippet: Samples were applied to the antigen coated plate and incubated at RT for 2 h. The plates were washed three times with PBST and HRP-conjugated antibodies were used to detect antigen-specific antibodies: anti-mouse IgG1 (#1070-05), anti-mouse IgG2a (#1080-05), anti-mouse IgG2b (#1090-05) and anti-mouse IgG3 (#1100-05) from Southern Biotech (Birmingham, AL, USA).

Techniques: Positive Control, Clinical Proteomics

Journal: medRxiv

Article Title: Serological Analysis Reveals an Imbalanced IgG Subclass Composition Associated with COVID-19 Disease Severity

doi: 10.1101/2020.10.07.20208603

Figure Lengend Snippet: Reactivity of IgM, IgA, and IgG specific to the SARS-CoV-2 nucleocapsid, RBD, S1 subunit, or S2 subunit of the full patient cohort (a ) or grouped by disease severity (b) . Index value represents the raw MFI divided by the background cutoff value determined by a panel of 93 normal human serum specimens. Statistical significance was determined by the non-parametric Kruskall-Wallace test where * p ≥ 0.05 ** p ≥ 0.001 *** p ≥ 0.0001, and **** p ≥ 0.00001.

Article Snippet: R-phycoerythrin (PE)-conjugated goat anti-human Ig, goat anti-human IgG, anti-human IgM, anti-human IgA, mouse anti-human IgG1, mouse anti-human IgG2, mouse anti-human IgG3, and mouse anti-human IgG4 were purchased (Southern Biotech).

Techniques:

Journal: medRxiv

Article Title: Serological Analysis Reveals an Imbalanced IgG Subclass Composition Associated with COVID-19 Disease Severity

doi: 10.1101/2020.10.07.20208603

Figure Lengend Snippet: (a) Reactivity of IgG1, IgG2, and IgG3 to SARS-CoV-2 nucleocapsid, RBD, S1 subunit, or S2 subunit of the full patient cohort (b) or grouped by disease severity. Index value represents the raw MFI divided by the background cutoff value determined by a panel of 93 normal human serum specimens. Statistical significance was determined by the non-parametric Kruskall-Wallace test where * p ≤ 0.05 ** p ≤ 0.001 *** p ≤ 0.0001, and **** p ≤ 0.00001.

Article Snippet: R-phycoerythrin (PE)-conjugated goat anti-human Ig, goat anti-human IgG, anti-human IgM, anti-human IgA, mouse anti-human IgG1, mouse anti-human IgG2, mouse anti-human IgG3, and mouse anti-human IgG4 were purchased (Southern Biotech).

Techniques:

Journal: medRxiv

Article Title: Serological Analysis Reveals an Imbalanced IgG Subclass Composition Associated with COVID-19 Disease Severity

doi: 10.1101/2020.10.07.20208603

Figure Lengend Snippet: (a) Three-dimensional scatter plot depicting the optimal feature set of disease severity-associated features (age, log10-transformed index values (MFI/cutoff) for S1-specific IgG3, and RBD-specific IgG1) as determined by ordered probit regression and backwards stepwise selection by Akaike information criterion. Data is displayed as the distribution of mild (yellow), moderate (orange), and severe (red) disease severities across variables in 478 patients.

Article Snippet: R-phycoerythrin (PE)-conjugated goat anti-human Ig, goat anti-human IgG, anti-human IgM, anti-human IgA, mouse anti-human IgG1, mouse anti-human IgG2, mouse anti-human IgG3, and mouse anti-human IgG4 were purchased (Southern Biotech).

Techniques: Transformation Assay, Selection

Journal: medRxiv

Article Title: Serological Analysis Reveals an Imbalanced IgG Subclass Composition Associated with COVID-19 Disease Severity

doi: 10.1101/2020.10.07.20208603

Figure Lengend Snippet: (a) IgG/Subclass index ratios for IgG1, 2, and 3 specific to the nucleocapsid, RBD, S1, and S2 subunits in mild, moderate, and severe patients. (b) Heat map represents the average MFI of each severity group divided by the average MFI of the entire data set. * denotes statistical significance. (c) Spearman’s correlation coefficient comparing the IgG response to the PRNT90 neutralizing titer.

Article Snippet: R-phycoerythrin (PE)-conjugated goat anti-human Ig, goat anti-human IgG, anti-human IgM, anti-human IgA, mouse anti-human IgG1, mouse anti-human IgG2, mouse anti-human IgG3, and mouse anti-human IgG4 were purchased (Southern Biotech).

Techniques: